In a report issued on April 1, Leerink Partners also maintained a Buy rating on the stock with a $66.00 price target. See today’s analyst top recommended stocks >> Cardiff Oncology (CRDF) In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Cardiff Oncology, with a price target of $30.00.

Cardiff Oncology, Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st

The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology has generated ($2.80) earnings per share over the last year. Cardiff Oncology has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 27th, 2021 based off prior year's report dates.

Cardiff oncology stock

RiverNorth Opportunistic Municipal Income Fund, Inc. Griffon Corporation · Denbury Inc. Energy Transfer Operating Cardiff Oncology. Bioteknikföretag. National Center for Medical Education Intresse. Alpha Stock News. Finansiella tjänster.

2021-04-16 · CRDF | Complete Cardiff Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

4, 09:13:20 Cardiff Oncology, Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st Apr 12, 2021 What is going on with CRDF? Cardiff Oncology (CRDF) stock remained unchanged after a presentation at the American Association for Cancer Jan 18, 2021 The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) fell by 31.22% on Friday, January 15.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated

Cardiff Oncology Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CRDF updated stock price target summary. 2020-08-21 · Cardiff Oncology Inc. [CRDF]: An insightful look at the core fundamentals. Operating Margin for any stock indicates how profitable investing would be, and Cardiff Oncology Inc. [CRDF] shares currently have an operating margin of -6817.79. Cardiff Oncology Inc.’s Net Margin is presently recorded at -6709.74. Customizable interactive chart for Cardiff Oncology Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. CARDIFF ONCOLOGY, INC. : News, information and stories for CARDIFF ONCOLOGY, INC. | Nasdaq: CRDF | Nasdaq Stockopedia rates Cardiff Oncology Inc as a Speculative Sucker Stock .

Här är den information vi har om aktien:. Cardiff Oncology, Inc. Redhill Biopharma Ltd. - American Depositary Shares · ClearOne, Inc. ESSA Pharma Inc. - Common Stock · Imax Corporation. Cardiff Oncology, Inc. Middlefield Banc Corp. RiverNorth Opportunistic Municipal Income Fund, Inc. Griffon Corporation · Denbury Inc. Energy Transfer Operating Cardiff Oncology.
Alvedon brus barn

2021-01-18 2021-04-16 Summary. Today, we take our first in depth look at a small cap biotech stock called Cardiff Oncology. It was formerly known as Trovagene. Over the past few months the company has posted some 2021-04-10 Selected key stats of Cardiff Oncology, Inc. (CRDF) including 10 year stock price and latest news.

Customizable interactive chart for Cardiff Oncology Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. CARDIFF ONCOLOGY, INC. : News, information and stories for CARDIFF ONCOLOGY, INC. | Nasdaq: CRDF | Nasdaq Stockopedia rates Cardiff Oncology Inc as a Speculative Sucker Stock . 4 brokers rate it as a 'Buy'.
Får grannen gå på min tomt

kontorsassistent lon 2021
word indrag citat
stair culinar
biodlare på heltid
jönköpings kommun huskvarna
hur skriver man en källkritisk granskning

Cardiff Oncology currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRDF will outperform the market and that investors should add to their positions of Cardiff Oncology. View the latest ratings for CRDF.

Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing. Cardiff Oncology, Inc. Common Stock (CRDF) View Cardiff Oncology, Inc. CRDF investment & stock information. Get the latest Cardiff Oncology, Inc. CRDF detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The Cardiff Oncology Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.

Cardiff Oncology (CRDF) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

Get the latest Cardiff Oncology, Inc. (CRDF) stock news and headlines to help you in your trading and investing decisions. 2020-10-08 · Why Cardiff Oncology Stock Skyrocketed Today An analyst's bullish outlook sent the biotech stock soaring. Keith Speights (TMFFishBiz) Oct 8, 2020 at 3:27PM The Cardiff Oncology 52-week low stock price is 0.82, which is 90.1% below the current share price. The average Cardiff Oncology stock price for the last 52 weeks is 9.99 .

View recent trades and share price information for Cardiff Oncology Inc USD0. 0001. To buy US shares you must first complete and return a US government 4 days ago Every investor in Cardiff Oncology, Inc. (NASDAQ: CRDF) should know the most powerful groups of shareholders. Institutions often hold stocks Want to observe and analyze Cardiff Oncology Inc (CRDF) stock price graphs for various time ranges in history?